Ryan K Orosco1, Elamprakash N Savariar2, Philip A Weissbrod1, Julio A Diaz-Perez3, Michael Bouvet4, Roger Y Tsien2,5, Quyen T Nguyen1. 1. Department of Surgery, Division of Head and Neck Surgery, University of California San Diego, San Diego, California. 2. Department of Pharmacology, University of California San Diego, San Diego, California. 3. Department of Pathology, Moores Cancer Center, University of California San Diego, La Jolla, California. 4. Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, California. 5. Howard Hughes Medical Institute, University of California San Diego, San Diego, California.
Abstract
BACKGROUND AND OBJECTIVES: Molecularly targeted fluorescent molecules may help detect tumors that are unseen by traditional white-light surgical techniques. We sought to evaluate a fluorescent ratiometric activatable cell penetrating peptide (RACPP) for tumor detection in a transgenic model of PTC. METHODS: Thirteen BRAFV600E mice with PTC were studied-seven injected intravenously with RACPP, four controls with saline. Total thyroidectomy was performed with microscopic white-light visualization. Fluorescent imaging of post-thyroidectomy fields was performed, and tissue with increased signal was removed and evaluated for PTC. Final samples were analyzed by a pathologist blinded to conditions. Vocal cord function was evaluated postoperatively with video laryngoscopy. RESULTS: The average in situ ratiometric (Cy5/Cy7) thyroid tumor-to-background contrast ratio was 2.27 +/- 0.91. Fluorescence-guided clean-up following thyroidectomy identified additional tumor in 2 of 7 RACPP animals (smallest dimension 1.2 mm), and decreased the number of animals with residual tumor from 4 to 3. All retained tumor foci on final pathology were smaller than 0.76 mm. Intact vocal abduction was present in all of the RACPP animals. CONCLUSIONS: RACPPs successfully targeted PTC in a transgenic thyroidectomy model, and allowed for residual tumor detection that reduced positive margins beyond what was possible with white-light surgery alone.
BACKGROUND AND OBJECTIVES: Molecularly targeted fluorescent molecules may help detect tumors that are unseen by traditional white-light surgical techniques. We sought to evaluate a fluorescent ratiometric activatable cell penetrating peptide (RACPP) for tumor detection in a transgenic model of PTC. METHODS: Thirteen BRAFV600Emice with PTC were studied-seven injected intravenously with RACPP, four controls with saline. Total thyroidectomy was performed with microscopic white-light visualization. Fluorescent imaging of post-thyroidectomy fields was performed, and tissue with increased signal was removed and evaluated for PTC. Final samples were analyzed by a pathologist blinded to conditions. Vocal cord function was evaluated postoperatively with video laryngoscopy. RESULTS: The average in situ ratiometric (Cy5/Cy7) thyroid tumor-to-background contrast ratio was 2.27 +/- 0.91. Fluorescence-guided clean-up following thyroidectomy identified additional tumor in 2 of 7 RACPP animals (smallest dimension 1.2 mm), and decreased the number of animals with residual tumor from 4 to 3. All retained tumor foci on final pathology were smaller than 0.76 mm. Intact vocal abduction was present in all of the RACPP animals. CONCLUSIONS: RACPPs successfully targeted PTC in a transgenic thyroidectomy model, and allowed for residual tumor detection that reduced positive margins beyond what was possible with white-light surgery alone.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park Journal: Cancer Date: 2011-08-31 Impact factor: 6.860
Authors: Tao Jiang; Emilia S Olson; Quyen T Nguyen; Melinda Roy; Patricia A Jennings; Roger Y Tsien Journal: Proc Natl Acad Sci U S A Date: 2004-12-15 Impact factor: 11.205
Authors: M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier Journal: J Clin Endocrinol Metab Date: 1986-10 Impact factor: 5.958
Authors: Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin Journal: Cancer Res Date: 2009-06-01 Impact factor: 12.701
Authors: Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: Elamprakash N Savariar; Csilla N Felsen; Nadia Nashi; Tao Jiang; Lesley G Ellies; Paul Steinbach; Roger Y Tsien; Quyen T Nguyen Journal: Cancer Res Date: 2012-11-27 Impact factor: 12.701
Authors: Kara K Rossfeld; Steven E Justiniano; Haiming Ding; Li Gong; Shankaran Kothandaraman; Dwitiya Sawant; Motoyasu Saji; Chadwick L Wright; Lawrence S Kirschner; Matthew D Ringel; Michael F Tweedle; John E Phay Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958